
2009

Biologically Derived Airborne Contaminants

Contents

Committee Members.....	236
Introduction.....	237
Biologically Derived Agents Under Study.....	240

BDAC

2008 BIOAEROSOLS COMMITTEE

Joseph Torey Nalbone, MS, PhD, CIH — Chair
Paula H. Vance, SM(ASCP), SM(NRM) — Vice Chair
Michael S. Crandall, CIH, MSEE
Michael L. Muilenberg, MS
Francis (Bud) J. Offermann, CIH, PE
Carol Y. Rao, CIH, ScD, MS
Linda D. Stetzenbach, PhD, MS

BDAC

***Help ensure the continued development of
TLVs® and BEIs®. Make a tax deductible donation to
the FOHS Sustainable TLV®/BEI® Fund today!***

<http://www.fohs.org/SusTLV-BEIPrgm.htm>

INTRODUCTION TO THE BIOLOGICALLY DERIVED AIRBORNE CONTAMINANTS

Biologically derived airborne contaminants include bioaerosols (airborne particles composed of or derived from living organisms) and volatile organic compounds that organisms release. Bioaerosols include microorganisms (i.e., culturable, nonculturable, and dead microorganisms) and fragments, toxins, and particulate waste products from all varieties of living things. Biologically derived contaminants are ubiquitous in nature and may be modified by human activity. Humans are repeatedly exposed, day after day, to a wide variety of such materials.

TLVs® exist for certain substances of biological origin, including cellulose; some wood, cotton, flour and grain dusts; nicotine; pyrethrum; starch; subtilisins (proteolytic enzymes); sucrose; vegetable oil mist; and volatile compounds produced by living organisms (e.g., ammonia, carbon dioxide, ethanol, and hydrogen sulfide). However, for the reasons identified below, there are no TLVs® against which to compare environmental air concentrations of most materials of biological origin.

ACGIH® has developed and separately published guidance on the assessment, control, remediation, and prevention of biologically derived contamination of indoor environments.⁽¹⁾ Indoor biological contamination is defined as the presence of a) biologically derived aerosols, gases, and vapors of a kind and concentration likely to cause disease or predispose humans to disease; b) inappropriate concentrations of outdoor bioaerosols, especially in buildings designed to prevent their entry; or c) indoor microbial growth and remnants of biological growth that may become aerosolized and to which humans may be exposed. The term “biological agent” refers to a substance of biological origin that is capable of producing an adverse effect, e.g., an infection or a hypersensitivity, irritant, inflammatory, or other response.

The ACGIH®-recommended approach to assessing and controlling bioaerosol exposures relies on visually inspecting buildings, assessing occupant symptoms, evaluating building performance, monitoring potential environmental sources, and applying professional judgment. The published guidance provides background information on the major groups of bioaerosols, including their sources and health effects, and describes methods to collect, analyze, and interpret bioaerosol samples from potential environmental sources. Occasionally, environmental monitoring detects a single or predominating biological contaminant. More commonly, monitoring reveals a mixture of many biologically derived materials, reflecting the diverse and interactive nature of indoor microenvironments. Therefore, environmental sampling for bioaerosols should be conducted only following careful formulation of testable hypotheses about potential bioaerosol sources and mechanisms by which workers may be exposed to bioaerosols from these sources. Even when investigators work from testable hypotheses and well-formulated sampling plans, results from environmental bioaerosol monitoring may be inconclusive and occasionally misleading.

There are no TLVs® for interpreting environmental measurements of a) total culturable or countable bioaerosols (e.g., total bacteria or fungi); b) specific culturable or countable bioaerosols (e.g., *Aspergillus fumigatus*); c) infectious agents (e.g., *Legionella pneumophila* or *Mycobacterium tuberculosis*); or d) assayable biological contaminants (e.g., endotoxin, mycotoxin, antigens, or microbial volatile organic compounds) for the following reasons.

A. Total culturable or countable bioaerosols. Culturable bioaerosols are those bacteria and fungi that can be grown in laboratory culture. Such results are reported as the number of colony-forming units (CFU). Countable bioaerosols are those pollen grains, fungal spores, bacterial cells, and other material that can be identified and counted by microscope. A general TLV® for culturable or countable bioaerosol concentrations is not scientifically supportable because of the following:

1. Culturable microorganisms and countable biological particles do not comprise a single entity, i.e., bioaerosols in occupational settings are generally complex mixtures of many different microbial, animal, and plant particles.
2. Human responses to bioaerosols range from innocuous effects to serious, even fatal, diseases, depending on the specific material involved and workers' susceptibility to it. Therefore, an appropriate exposure limit for one bioaerosol may be entirely inappropriate for another.
3. It is not possible to collect and evaluate all bioaerosol components using a single sampling method. Many reliable methods are available to collect and analyze bioaerosol materials. However, different methods of sample collection and analysis may result in different estimates of culturable and countable bioaerosol concentrations.
4. At present, information relating culturable or countable bioaerosol concentrations to health effects is generally insufficient to describe exposure–response relationships.

B. Specific culturable or countable bioaerosols other than infectious agents. Specific TLVs® for individual culturable or countable bioaerosols have not been established to prevent hypersensitivity, irritant, or toxic responses. At present, information relating culturable or countable bioaerosol concentrations to health effects consists largely of case reports and qualitative exposure assessments. The data available are generally insufficient to describe exposure–response relationships. Reasons for the absence of good epidemiologic data on such relationships include the following:

1. Most data on concentrations of specific bioaerosols are derived from indicator measurements rather than from measurements of actual effector agents. For example, investigators use the air concentration of culturable fungi to represent exposure to airborne fungal antigens. In addition, most measurements are from either area or source samples. These monitoring approaches are less likely to reflect human exposure accurately than would personal sampling for actual effector agents.
2. Bioaerosol components and concentrations vary widely within and among different occupational and environmental settings. Unfortunately, replicate sampling is uncommon in bioaerosol assessments. Further, the most commonly used air-sampling devices for indoor monitoring are designed to collect “grab” samples over relatively short time intervals. Measurements from single, short-term grab samples may be orders of magnitude higher or lower than long-term average concentrations and are unlikely to represent workplace exposures accurately. Some organisms and sources release aerosols as “concentration bursts,” which may only rarely be detected by limited grab sampling. Nevertheless, such episodic bioaerosol releases may produce signifi-

cant health effects.

3. In studies of single workplaces, the number of persons affected by exposure to biological agents may be small if contamination is localized, thereby affecting only a fraction of the building occupants. However, data from different studies can seldom be combined to reach meaningful numbers of test subjects because the specific types of biological agents responsible for bioaerosol-related illnesses are diverse and often differ from study to study. These factors contribute to the low statistical power common in evaluations of cause–effect relationships between exposures to specific biological agents and building-related health complaints.

C. Infectious agents. Human dose–response data are available for only a few infectious bioaerosols. At present, air-sampling protocols for infectious agents are limited and suitable primarily for research endeavors. In most routine exposure settings, public health measures, such as immunization, active case finding, and medical treatment, remain the primary defenses against infectious bioaerosols. Facilities associated with increased risks for transmission of airborne infectious diseases (e.g., microbiology laboratories, animal-handling facilities, and health-care settings) should employ engineering controls to minimize air concentrations of infectious agents. Further, such facilities should consider the need for administrative controls and personal protective equipment to prevent the exposure of workers to these bioaerosols.

D. Assayable biological contaminants. Assayable, biologically derived contaminants (e.g., endotoxin, mycotoxins, antigens, and volatile organic compounds) are microbial, animal, or plant substances that can be detected using chemical, immunological, or biological assays. Evidence does not yet support TLVs® for any of these substances. However, assay methods for certain common airborne antigens and endotoxin are steadily improving, and field validation of these assays is also progressing. Dose–response relationships for some assayable bioaerosols have been observed in experimental studies and occasionally in epidemiologic surveys. Therefore, exposure limits for certain assayable, biologically derived, airborne contaminants may be appropriate in the future. In addition, innovative molecular techniques are becoming available for specific bioaerosols currently detectable only by culture or counting.

ACGIH® actively solicits information, comments, and data in the form of peer-reviewed literature on health effects associated with bioaerosol exposures in occupational and related environments that may help the Bioaerosols Committee evaluate the potential for proposing exposure guidelines for selected biologically derived airborne contaminants. Such information should be sent, preferably in electronic format, to The Science Group, ACGIH® (science@acgih.org).

Reference

1. ACGIH®: Bioaerosols: Assessment and Control. JM Macher, Ed; HM Ammann, HA Burge, DK Milton, and PR Morey, Asst. Eds. ACGIH®, Cincinnati, OH (1999).

BIOLOGICALLY DERIVED AGENTS UNDER STUDY

The Bioaerosols Committee solicits information, especially data, which may assist it in the establishment of TLVs® for biologically derived airborne contaminants. Comments and suggestions, accompanied by substantiating evidence in the form of peer-reviewed literature, should be forwarded in electronic format to The Science Group, ACGIH® (science@acgih.org).

The substances and issues listed below are as of January 1, 2009. *After this date, please refer to the ACGIH® website (<http://www.acgih.org/TLV/Studies.htm>) for the up-to-date list.*

Agents

gram negative bacterial endotoxin
(1-3) beta, D-glucan